ストックスクリーナーアプリを入手
10.39
0.10%
-0.010
アフターアワーズ：
10.26
-0.13
-1.25%
前日終値:
$10.40
開ける：
$10.4
24時間の取引高:
1.84M
Relative Volume:
1.18
時価総額：
$3.26B
収益：
$2.68B
当期純損益:
$-184.45M
株価収益率:
-15.27
EPS:
-0.6805
ネットキャッシュフロー:
$229.23M
1週間 パフォーマンス:
+6.56%
1か月 パフォーマンス:
+8.91%
6か月 パフォーマンス:
+33.03%
1年 パフォーマンス:
+21.52%
1日の値動き範囲:
$10.37
$10.68
1週間の範囲:
$9.66
$10.68
52週間の値動き範囲:
$6.685
$10.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
10.39 | 3.27B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
146.42 | 64.92B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.60 | 45.60B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.95 | 39.54B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.01 | 23.00B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
453.07 | 20.06B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-02-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | アップグレード | Goldman | Sell → Buy |
| 2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-27 | 開始されました | Goldman | Sell |
| 2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
| 2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
| 2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 開始されました | Morgan Stanley | Overweight |
| 2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Amneal Pharmaceuticals Hits New 52-Week High of $10.43 - Markets Mojo
Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market - MSN
Sentiment analysis tools applied to Amneal Pharmaceuticals Inc.2025 Price Targets & Weekly High Return Stock Opportunities - newser.com
What to expect from Amneal Pharmaceuticals Inc. in the next 30 daysQuarterly Market Review & Accurate Buy Signal Notifications - newser.com
Will breakout in Amneal Pharmaceuticals Inc. lead to full recoveryTrade Entry Report & Short-Term Trading Opportunity Alerts - newser.com
Measuring Amneal Pharmaceuticals Inc.’s beta against major indicesDay Trade & Capital Efficiency Focused Strategies - newser.com
Is Amneal Pharmaceuticals Inc. stock cheap compared to fundamentalsEarnings Growth Report & Safe Entry Zone Identification - newser.com
Chart based exit strategy for Amneal Pharmaceuticals Inc.Market Volume Summary & Smart Investment Allocation Insights - newser.com
Reversal indicators forming on Amneal Pharmaceuticals Inc. stockInsider Buying & Real-Time Market Trend Scan - newser.com
Will Amneal Pharmaceuticals Inc. price bounce be sustainable2025 Big Picture & AI Forecasted Stock Moves - newser.com
Using Python tools to backtest Amneal Pharmaceuticals Inc. strategiesQuarterly Earnings Summary & Stepwise Trade Execution Plans - newser.com
What analysts say about Amneal Pharmaceuticals Inc stockGap Up/Gap Down Analysis & Free Take Advantage Of Momentum - earlytimes.in
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - sharewise.com
3 Lesser-Known Healthcare Names With Major Upside in Store - sharewise.com
3 Lesser-Known Healthcare Names With Major Upside in Store - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at $10.36 By Investing.com - Investing.com Canada
Amneal Pharmaceuticals stock hits 52-week high at $10.36 - Investing.com
Technical analysis overview for Amneal Pharmaceuticals Inc. stock2025 Big Picture & Technical Buy Zone Confirmations - newser.com
Published on: 2025-10-01 09:03:57 - newser.com
Is it time to cut losses on Amneal Pharmaceuticals Inc.2025 Market Sentiment & Breakout Confirmation Alerts - newser.com
Applying Wyckoff theory to Amneal Pharmaceuticals Inc. stock2025 Momentum Check & Verified High Yield Trade Plans - newser.com
Amneal to Report Third Quarter 2025 Results on October 30, 2025 - The Manila Times
Global Biopharma Amneal Pharmaceuticals Schedules Q3 2025 Financial Results and Investor Conference - Stock Titan
Amneal Files Xolair Biosimilar In US ‘Earlier Than Expected’ - insights.citeline.com
Amneal Pharmaceuticals Inc Stock Analysis and ForecastDividend Stability Analysis & Explosive Profit Trading - earlytimes.in
How to read the order book for Amneal Pharmaceuticals Inc.2025 Institutional Moves & Fast Exit Strategy with Risk Control - newser.com
What drives Amneal Pharmaceuticals Inc stock priceRisk-Reward Ratio Analysis & Low Cost Stock Picks - Early Times
Amneal gets FDA nod for generic version of Risperdal Consta - MSN
Amneal submits biosimilar application for asthma drug Xolair - Investing.com India
Amneal submits biosimilar application for asthma drug Xolair By Investing.com - Investing.com South Africa
Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis - Seeking Alpha
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab) - The Manila Times
Amneal announces BLA submission of biosimilar candidate to Xolair (omalizumab) - MarketScreener
$4.1 Billion Market Opportunity: Amneal's XOLAIR Biosimilar Filing Could Transform Asthma Treatment Access - Stock Titan
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
0.83%
9.21%
大文字化:
|
ボリューム (24 時間):